Doctors have to navigate a vast amount of medical knowledge to find the right information at the right time. Founded by a team of physicians in Germany, AMBOSS has transformed the way medical knowledge is acquired and applied at the point of care.
Now, AMBOSS has secured €240 million in financing to fuel its next phase of growth. The funding came from new long-term investors KIRKBI, M&G Investments, and Lightrock, alongside participation from existing shareholders.
It will accelerate AMBOSS’s expansion into new international markets and extend its offerings beyond physicians. This new capital will help the company empower a broader range of healthcare professionals, including nurses and allied health providers, ensuring they have access to the same world-class medical knowledge that physicians currently rely on.
In addition to the funding, AMBOSS recently converted to a European stock corporation (SE). This decision to convert to a European stock corporation (SE) reflects its long-term vision of becoming a global leader in digital healthcare solutions. This transition positions the company to strengthen its market leadership, maintain regulatory compliance across international borders, and ensure sustainable growth as it scales its operations globally.
Empowers the next generation of healthcare professionals
AMBOSS was founded in 2012 by a team of physicians: Ehsan Khaljani, Madjid Salimi, Benedikt Hochkirchen, and Sievert Weiss. As a global medical knowledge platform, it empowers healthcare professionals by providing evidence-based, real-time guidance that enhances clinical decision-making and supports medical education.
Since then, the company has grown to include over 500 employees from more than 50 countries, comprising scientists, software engineers, and more than 150 physicians, demonstrating its commitment to bridging the gap between medical knowledge and technological innovation.
The platform integrates high-quality, peer-reviewed medical content with cutting-edge AI to deliver actionable insights for diagnostics and treatment. This approach enables physicians to make informed decisions quickly, reducing treatment errors and improving patient outcomes. AMBOSS’s user-centered model ensures that medical expertise is always at a physician’s fingertips—whether they are preparing for an exam or managing complex clinical cases.
AMBOSS’s platform includes several innovative features, such as diagnostic approaches, management overviews, flowcharts, and acute management checklists designed to help physicians navigate complex clinical decisions efficiently and accurately.
A critical factor behind AMBOSS’s success is its strong in-house collaboration between experienced medical experts and technology specialists. The platform leverages AI to provide precise, up-to-date recommendations that adhere to the latest clinical guidelines, enabling clinicians to deliver safe and effective care. AMBOSS serves as a digital co-pilot for healthcare professionals, helping them save valuable time while minimising the risk of diagnostic and treatment errors.
In the US, AMBOSS is claimed to be an essential tool for medical students, with the majority relying on the platform to prepare for critical exams and achieve higher scores than with traditional question banks. 25% of first-year US residents trust AMBOSS to support their clinical decision-making as they transition into residency and provide high-quality patient care. In Germany, AMBOSS plays an equally vital role, with every second inpatient treatment being carried out by a physician who uses the platform to guide their decision-making.
With a rapidly growing user base of over 1 million healthcare professionals in 180 countries, AMBOSS has become a trusted resource for clinicians and students alike.
Responsible AI integration for enhanced clinical decision-making
AI has played a major role in shaping the AMBOSS experience, and the company remains committed to responsible AI integration. By rigorously validating outcomes and maintaining a value-first approach, AMBOSS ensures that its technology remains a trusted companion for clinicians. The AI-powered platform distills vast amounts of medical information into concise, actionable insights, enabling healthcare professionals to stay current with evolving guidelines while focusing on delivering personalised patient care.
Its commitment to ethical AI practices reinforces trust among users and strengthens its reputation as a reliable partner in medical education and clinical practice. As AI continues to evolve, AMBOSS is well-positioned to lead the charge in delivering innovative, validated solutions that enhance the healthcare experience.
Looking ahead: a potential IPO?
As AMBOSS embarks on this new chapter, the company remains committed to its mission of empowering healthcare professionals with the knowledge they need to provide exceptional care. With the backing of long-term investors and a proven track record of innovation, AMBOSS is poised to shape the future of medical education and clinical decision-making on a global scale.
“We choose investors who are committed to our long-term vision and very flexible in the investment duration. Many of our new investors manage evergreen funds and plan to accompany us until a possible IPO and beyond,” commented Benedikt Hochkirchen, Co-Founder and co-CEO of AMBOSS. “Additional funds will go into further investment in technology and new market segments. Selective acquisitions will also continue to be part of our strategy.” In 2024, AMBOSS acquired Novaheal, a start-up in the nursing field, and NEJM Knowledge+, a board exam prep product for residents in the US. The recent financing round significantly improves access to capital for AMBOSS.
“Technology will not replace health care professionals, but those who embrace it will lead the way,” said Dr. Madjid Salimi, Co-Founder and co-CEO of AMBOSS.
Peter Bason, Head of Private Capital at KIRKBI, added, “We have followed AMBOSS’ impressive growth journey, from its successful US expansion to its strong focus on innovation. Its unique platform is becoming a vital tool for both medical students and healthcare professionals, supporting learning and decision-making at every stage. We are excited to partner with other experienced technology and growth investors to back AMBOSS’ visionary leadership team in their mission of empowering the next generation of health care professionals worldwide.”
The post AMBOSS raises €240M, eyeing IPO: Can this digital co-pilot for physicians redefine medical knoweledge? appeared first on Tech Funding News.